Jasper Therapeutics shares are trading higher after BTIG initiated coverage on the stock with a Buy rating and a $90 price target.
Portfolio Pulse from Benzinga Newsdesk
Jasper Therapeutics shares are trading higher after BTIG initiated coverage on the stock with a Buy rating and a $90 price target.
July 08, 2024 | 11:23 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Jasper Therapeutics shares are trading higher after BTIG initiated coverage on the stock with a Buy rating and a $90 price target.
BTIG's initiation of coverage with a Buy rating and a high price target of $90 is a strong positive signal for investors, likely driving the stock price higher in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100